IL-9 and Mast Cells Are Key Players of *Candida albicans* Commensalism and Pathogenesis in the Gut

**Graphical Abstract**

**Highlights**

- IL-9/IL-9R signaling affects MC function in mucosal candidiasis
- IL-9 and mucosal MCs contribute to barrier function loss in leaky gut models
- IL-9 and stromal MCs induce local protective tolerance in infection via IDO1
- IL-9 and mucosal MCs expand and IDO1 decreases in human celiac disease

**Authors**

Giorgia Renga, Silvia Moretti, Vasilis Oikonomou, ..., Luigi Maiuri, Carlo Pucillo, Luigina Romani

**Correspondence**

luigina.romani@unipg.it

**In Brief**

Deciphering the mechanisms by which *Candida albicans* promotes either pathology or protective tolerance in the gut could be clinically relevant. Renga et al. show a key role for IL-9 and mast cells in promoting either inflammatory dysbiosis and pathology or tolerance in leaky gut models and human celiac disease.
IL-9 and Mast Cells Are Key Players of *Candida albicans* Commensalism and Pathogenesis in the Gut

Giorgia Renga, Silvia Moretti, Vasilis Oikonomou, Monica Borghi, Teresa Zelante, Giuseppe Paolicelli, Claudio Costantini, Marco De Ziani, Valeria Rachela Villella, Valeria Raia, Rachele Del Sordo, Andrea Bartoli, Monia Baldoni, Jean-Christophe Renaud, Angelo Sidoni, Enrico Garaci, Luigi Maiuri, Carlo Pucillo, and Luigina Romani

**INTRODUCTION**

*Candida albicans* is well adapted for growth in the gastrointestinal tract, where the colonization levels reflect an interplay between host immunity, the microbiota, and the fungus (Noble et al., 2017; Romani, 2011; Underhill and Pearlman, 2015). Much like antibiotics, intestinal inflammation may perturb the resident bacterial community, creating conditions that favor both high-level *Candida* colonization and inflammation. However, despite being implicated in gut immunopathology (Gerard et al., 2015), including celiac disease (CD) (McDermott et al., 2003; Nieuwenhuizen et al., 2003) and sensitization to food antigens (Yamaguchi et al., 2006), *C. albicans* colonization protects against local (Bonifazi et al., 2009; Montagnoli et al., 2002) and distant (Noverr and Huffnagle, 2004) immune pathologies in mice. In humans, the clinical significance of fungi in gastrointestinal diseases is still controversial, and the need for antifungal therapy has not reached a consensus (Sasaki, 2012). Thus, identifying host signatures that discriminate between the pathogenic versus protective role of the fungus becomes important.

Recent studies have suggested the possible participation of mast cells (MCs) in *Candida* host interaction at mucosal surfaces (Lopes et al., 2015; Schlapbach et al., 2014). *In vitro*, human MCs mount a specific temporal pattern of responses toward *C. albicans* that includes an initial phase characterized by secretion of granular proteins, neutrophil recruitment, and reduced fungal viability, followed by a late stage of release of mediators against local (Bonifazi et al., 2009; Montagnoli et al., 2002) and distant (Noverr and Huffnagle, 2004) immune pathologies in mice. Because of their strategic location at vascularized mucosal surfaces combined with a unique versatility (Frossi et al., 2017), MCs are well positioned to respond to allergens and pathogens and modulate mucosal immune responses (Abraham and St John, 2010; Reber et al., 2015), thus contributing to a wide variety of human infections and diseases (Frossi et al., 2017). The phenotypic and functional characteristics of MCs can be tuned by many genetic and environmental factors, including changes in the cytokine milieu associated with inflammatory or immune responses (Frossi et al., 2017; Galli et al., 2005). However, despite their potential phenotypic “plasticity,” two types of MCs have been described in mice based on their protease content and location: connective tissue-type MCs (CTMCs), and pathogenicity. By inducing TGF-β in stromal MCs, IL-9 pivotally contributes to mucosal immune tolerance via the indoleamine 2,3-dioxygenase enzyme. However, *Candida*-driven IL-9 and mucosal MCs also contribute to barrier function loss, dissemination, and inflammation in experimental leaky gut models and are upregulated in patients with celiac disease. Inflammatory dysbiosis occurs with IL-9 and MC deficiency, indicating that the activity of IL-9 and MCs may go beyond host immunity to include regulation of the microbiota. Thus, the output of the IL-9/MC axis is highly contextual during *Candida* colonization and reveals how host immunity and the microbiota finely tune *Candida* behavior in the gut.

**SUMMARY**

*Candida albicans* is implicated in intestinal diseases. Identifying host signatures that discriminate between the pathogenic versus commensal nature of this human commensal is clinically relevant. In the present study, we identify IL-9 and mast cells (MCs) as key players of *Candida* commensalism and pathogenicity. By inducing TGF-β in stromal MCs, IL-9 pivotally contributes to mucosal immune tolerance via the indoleamine 2,3-dioxygenase enzyme. However, *Candida*-driven IL-9 and mucosal MCs also contribute to barrier function loss, dissemination, and inflammation in experimental leaky gut models and are upregulated in patients with celiac disease. Inflammatory dysbiosis occurs with IL-9 and MC deficiency, indicating that the activity of IL-9 and MCs may go beyond host immunity to include regulation of the microbiota. Thus, the output of the IL-9/MC axis is highly contextual during *Candida* colonization and reveals how host immunity and the microbiota finely tune *Candida* behavior in the gut.
stomal tissue, and mucosal MCs (MMCs), of bone marrow origin and residing in the gut and lung (Gurish and Austen, 2012; Reber et al., 2015).

Among MCs, interleukin-9 (IL-9)-producing mucosal MCs (MMC9s) are the principal producers of IL-9 (~2.0 pg/mL per cell) (Chen et al., 2015), the key cytokine that autocrinally drives mastocytosis (Renault et al., 1990). MMC9s are scarce in the small intestines of immunologically naive mice and expand considerably after repeated ingested antigen exposure (Chen et al., 2015). In addition to MMC9s, innate lymphoid cells (ILCs) 2 and T helper (Th) 9 cells may also serve as alternative cellular sources of IL-9, thus amplifying intestinal mastocytosis involved not only in food allergy and systemic anaphylaxis (Chen et al., 2015; Shik et al., 2017) but also in intestinal inflammation (Boeckxstaens, 2015; Gerlach et al., 2014; Naileweg et al., 2015) and in the onset and progression of CD (Frossi et al., 2017). However, several lines of evidence show that MCs and IL-9 may also suppress chronic inflammatory responses and promote immune tolerance (de Vries and Noelle, 2010; Lu et al., 2006; Metz et al., 2007). Thus, by integrating multiple signals and mechanisms, MCs promote either inflammatory immunity or immune tolerance.

It has recently been reported that the MC–ILC2–Th9 pathway exacerbates aspergillosis and promotes lung inflammation in cystic fibrosis (CF) (Moretti et al., 2017). In candidiasis, Th9 responses were defective in patients with chronic mucocutaneous candidiasis (Becker et al., 2016) and abundant in Candida–driven skin inflammation (Schlapbach et al., 2014). Thus, a role for the IL-9/ILC axis in mucosal candidiasis is plausible but has never been directly demonstrated. In the present study, we reveal that IL-9 and MCs are key players of Candida pathogenicity at mucosal surfaces. IL-9 and mucosal MCs contributed to barrier function loss, dissemination, and inflammation in experimental models of impaired intestinal barrier function and were upregulated in patients with CD. However, by inducing the indoleamine 2,3-dioxygenase enzyme in response to the fungus, IL-9 pivotally contributed to local immune tolerance. Indeed, inflammatory dysbiosis occurred in the relative absence of IL-9 and MCs, a finding indicating that the activity of IL-9 and MCs may go beyond host immunity to include regulation of the microbiota.

RESULTS

The IL-9/IL-9R Signaling Pathway Is Involved in Innate and Th Immunity to C. albicans

We resorted to primary and secondary gastrointestinal infection in C57BL/6 and Il9R−/− mice to measure IL-9 production and IL9R expression in infection. Increased production of IL-9 and expression of IL9R were observed in the stomach of C57BL/6 but not Il9R−/− mice (Figures 1A and 1B), a finding suggesting that IL-9 production is IL-9R-dependent. Both innate and adaptive immune responses contributed to IL-9 production, as indicated by the high levels observed early and late in infection and protective effects in Ragg−/−Il9R−/− mice (Figure S1C). IL-9 production was not defective in IL-4- or IL-17RA-deficient mice (Figure S1C), which indicates that Th2 and Th17 cells do not contribute to IL-9 production, as suggested previously (Kaplan, 2013). Increased production of IL-9 was also observed in the ileum (from 20 ± 3 to 300 ± 13 pg/mL, naive versus 3-day infected mice) and colon (from 76 ± 6 to 540 ± 33 pg/mL, naive versus 3-day infected mice).

ILC2s, MMC9s, and Th9s are the most potent producers of IL-9 at mucosal surfaces (Kaplan, 2013; Wilhelm et al., 2011). We found that both ILC2s and Th9s (gating strategy shown in Figures S1A and S1B) produced IL-9 in infection, as indicated by flow cytometry (Figure 1C), and that expression of the Rora transcription factor of ILC2s and the Pu.1 and Irf4 transcription factors of Th9s (Figure 1D) were lower in Il9R−/− compared with C57BL/6 mice. Consistent with the significant reduction of IL-9 levels in MC-deficient C57BL/6-Kitw/wv mice (hereafter called Kitw/wv) (Figure 1A), IL-9+CD117+ MCs in the stomach (Figure 1F) and production of MC protease 1 (MCPT-1) (MCPT-1) (Figure 1G) were also lower in Il9R−/− compared with C57BL/6 mice. Gata3 and Foxp3, but not Tbet or Rorc, were poorly upregulated in Il9R−/− mice during infection (Figure 1E). Together with the lower production of the neutrophil chemoattractant KC and inflammatory tumor necrosis factor alpha (TNF–α), IL-17A, and IL-1β cytokines observed in Il9R−/− compared with C57BL/6 mice early in infection (Figure 1H), this immune profile would predict an effect of defective IL-9/IL-9R signaling on infection. This appeared to be the case because the loss of IL-9R signaling led to reduced...
inflammatory cell recruitment in the stomach (Figure 1J) and colon (inset in Figure 1J) and, paradoxically, reduced local fungal growth, particularly early in the course of infection (Figure 1I). Similar results were obtained in Rag2−/−Il9R−/− mice (Figure S1), suggesting that defective IL-9/IL-9R signaling in innate cells contributes to the increased resistance. Importantly, IL-9 ablation by means of neutralizing antibody and exogenous IL-9 administration increased or decreased, respectively, resistance to infection, as indicated by local fungal growth (Figure 1K) and the pattern of inflammatory cytokine production (Figure 1L), suggesting a causal role of IL-9 in impairing early antifungal resistance. Together, these results suggest that IL-9/IL-9R signaling is dispensable for resistance, if not contributing to pathogenic inflammation, during initial C. albicans infection.

Surprisingly, the effects of IL-9 ablation or administration were different late in infection, at a time when resistance to infection was instead promoted by IL-9 and impaired upon IL-9 inhibition. When testing the hypothesis of a possible disparate activity of IL-9 on innate and adaptive immunity to the fungus, we assessed Il9R−/− mice for resistance to re-infection and parameters of adaptive Th immunity. Il9R−/− mice were less resistant than C57BL/6 mice to re-infection, as indicated by decreased survival (Figure 2A), the inability to control fungal dissemination despite a degree of control of fungal growth locally (Figure 2B), and increased inflammatory pathology both in the stomach and the kidneys (Figure 2C). IL-9 production and Th9 cells were expectedly lower in Il9R−/− mice than in C57BL/6 mice (Figure 2D). In contrast, Th1/Th17 cell activation was higher but regulatory T cell (Treg) activation was lower and Th2 apparently was unaffected in Il9R−/− mice compared with C57BL/6 mice (Figure 2E), a finding pointing to dysfunctional Th responses under conditions of IL-9R deficiency, which could account for the failure to mount memory responses to the fungus (Montagnoli et al., 2002). Together, these results suggest a temporally distinct activity of IL-9 in infection being required for optimal Th/Treg-mediated protection but dispensable for innate antifungal defense.

The IL-9/IL-9R Signaling Pathway Regulates MC Activity in Infection

The above results prompted us to investigate the mechanisms behind the opposite activity of IL-9 in infection and re-infection. Given the ability of IL-9 to inhibit the oxidative burst of effector phagocytes (Pilette et al., 2002), IL-9 could adversely affect the activity of effector phagocytes. Although IL-9 slightly decreased the oxidative burst and candidacidal activity in vitro (Figure S2), the antifungal activity was not impaired in Il9R−/− mice (Figure S2). Thus, the reduced inflammatory response of Il9R−/− mice was not secondary to a reduced fungal growth. To unravel mechanisms uncoupling the inflammatory response from the fungal growth, we looked for MC expansion and activity in infection, considering that MCs promote neutrophil recruitment (Malaviya et al., 1996), regulate acquired immune responses (Galli et al., 2005), and are directly responsible for increasing epithelial paracellular

**Figure 2. The IL-9/IL-9R Signaling Pathway Provides Resistance to Re-infection**

(A) Survival (percent) of C57BL/6 and Il9R−/− mice subjected to secondary i.g. infection with C. albicans.

(B) Fungal growth (log_{10} CFUs).

(C) Histopathology (PAS; the scale bar represents 500 μm or 100 μm) in the stomach and kidney.

(D) IL-9 levels (ELISA) in stomach homogenates and expression of Pu.1 and Irf4 (RT-PCR) in CD4+ T cells from MLNs.

(E) Expression of Th cell-specific transcripts (RT-PCR) on CD4+ T cells from MLNs. Assays were done 3 days after re-infection. Data represent pooled results (n = 6, mean ± SD) or representative images from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001. NS, not significant. Il9R−/− versus C57BL/6 mice.

Statistical analyses of the survival curves were performed using the log rank (Mantel-Cox) test. Unpaired t test or two-way ANOVA, Bonferroni post test. Naive, uninfected mice.
permeability during intestinal infection via MCPT-1 (McDermott et al., 2003). MCs expanded early in the forestomach and glandular stomach of C57BL/6 mice and less in Il9R–/– mice to decline thereafter (from 1.83 ± 0.26 MCs/mm² in uninfected mice to 3.50 ± 0.70 and 2.40 ± 0.40 at 3 and 10 days post infection (dpi), respectively), as seen by toluidine blue staining (Figure S3A). Of interest, safranin-negative/Alcian blue-positive MCs were localized in the mucosa early in infection, whereas Alcian-blue negative/safranin-positive MCs were continuously present in the connective tissue, indicating that both MMCs and CTMCs, respectively, expanded in infection (Figure 3A).

Figure 3. The IL-9/IL-9R Signaling Pathway Regulates MC Activity in Infection
(A) Alcian blue/safranin staining (the scale bar represents 200 μm or 50 μm) with relative MC number per square millimeter in stomach sections of C57BL/6 and Il9R–/– mice infected i.g. with C. albicans.

(B) MC protease expression (RT-PCR) in the stomach.

(C) Degranulation percentage in BM-derived MC in the presence of IL-3 with (connective tissue MC [CTMC]) or without (mucosal MC [MMC]) stem cell factor and stimulated with C. albicans yeasts, hyphae, or IgE/Ag.

(D) MC morphometry (May-Grünwald-Giemsa staining) and percentage of phagocytosis (top line) and killing (bottom line) of MMCs and CTMCs pulsed for 2 hr with viable C. albicans yeasts or hyphae.

(E and F) MCPT-1 (E) and cytokine (F) production (ELISA) in culture supernatants of MMCs and CTMCs pulsed with the fungus for 5 hr with or without 10 ng/mL rIL-9.

To functionally characterize the MC subtypes, we cultivated bone marrow (BM)-derived MCs in the presence of IL-3, alone or with stem cell factor, to obtain MCs considered to be the tissue culture equivalent of MMCs or CTMCs, respectively (Godfraind et al., 1998). We stimulated MC subtypes with Candida and/or immunoglobulin E (IgE)/Ag (antigen) and looked for degranulation, phagocytosis, and killing of the fungus and cytokine production. Consistent with the ability of the fungus to degranulate human MCs at a high MOI only (Lopes et al., 2015), degranulation was not induced, if not inhibited, in either MC subtype in response to Candida yeasts or hyphae (Figure 3C). MC subtypes, despite being able to phagocytose unopsonized yeasts but not hyphae, exhibited different candidacidal activity, being MMCs unable to kill the ingested fungi (Figure 3D), as suggested previously (Trevisan et al., 2014). Actually, the massive MCPT-1 release would suggest MMC necrosis, an effect potentiated by IL-9 (Figure 3E). Killing of the ingested yeasts (Figure 3D) and no release of MCPT-1 (Figure 3E) were instead observed with CTMCs. Either MC subtype
produced IL-9 in response to Candida (Figure 3F), and IL-9 affected cytokine production (Figure 3F) but not the antifungal effector activity of MCs (data not shown). Indeed, MCs discriminated between the fungal morphotypes in terms of TGF-β and IL-10 production; CTMCs more than MMCs were able to release both cytokines in response to hyphae, a release potentiated by IL-9 (Figure 3F). No differences were observed in Il1b and Tnfa gene expression in either MC subtype (data not shown). These findings indicate that C. albicans exploits MC functional versatility at mucosal surfaces to contribute to local damage and inflammation or protection.

Indeed, consistent with the upregulated expression of the sealing protein occludin in the colon of Il9−/− mice (Gerlach et al., 2015), the occludin gene (Figure 4C) and protein expression (Figures 4D and 4E) were downregulated in C57BL/6 mice and upregulated in Il9−/− mice as well as in KitW/W−v mice either untreated or engrafted with wild-type but not Il9−/− BM-cultured MCs (BMMCs) in KitW/W−v mice (Figure 4B), a finding indicating that IL-9 and MC work together in promoting epithelial leakage.

IL-9 and MCs Affect Intestinal Epithelial Permeability and Adaptive Immunity

The effect of IL-9 on MCPT1 production would predict an effect on epithelial cell permeability. We used fluorescein isothiocyanate (FITC)-dextran to detect leakage in the early stages of permeability induction. Leakage was observed at 3 dpi in C57BL/6 mice and was dependent on both IL-9 and MCs, as evidenced by the reduced leakage in Il9−/− or KitW/W−v mice (Figure 4A). However, leakage was promoted upon IL-9 administration alone in C57BL/6 mice or together with engrafted wild-type but not Il9−/− BM-cultured MCs (BMMCs) in KitW/W−v mice (Figure 4B), a finding indicating that IL-9 and MC work together in promoting epithelial leakage.

Figure 4. MCs Regulate Intestinal Permeability and Adaptive Immunity in C. albicans Infection

(A) FITC-dextran levels in the serum of C57BL/6, Il9−/−, and KitW/W−v mice infected i.g. with C. albicans and treated for 3 days with 10 µg/kg rIL-9. (B) FITC-dextran levels in KitW/W−v mice engrafted intravenously with C57BL/6 or Il9−/− BM-cultured MCs (BMMCs), infected, and treated as in (A). Mice were sacrificed 3 dpi. (C) Occludin expression (RT-PCR) in the colon. (D) Expression of occludin by immunofluorescence and TUNEL staining in the gut of C57BL/6 and Il9−/− infected mice. (E) Occludin expression, TUNEL staining, and colon histopathology of KitW/W−v mice engrafted intravenously with C57BL/6 or Il9−/− BMMCs, infected i.g., and treated with rIL-9 for 3 days. (H&E; the scale bars represent 100 µm or 50 µm). (F) Fungal growth (log10 CFUs). (G) Cytokine expression (RT-PCR) in the colon of KitW/W−v mice. Data represent pooled results (n = 6, mean ± SD) or representative images from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, treated versus untreated mice and knockout versus C57BL/6 mice. One- or two-way ANOVA, Tukey’s or Bonferroni post test.
fungal growth and dissemination (Figure 4F), and inflammatory cytokine gene expression (Figure 4G) were reduced in KitW/W-v mice early in infection and promoted upon administration of wild-type but not Il9R–/– BMMCs with and without IL-9. Similar to Il9R–/– mice, KitW/W-v mice failed to control both fungal growth (Figure S3B) and inflammatory pathology (Figure S3C) upon re-infection and to activate memory-protective Th1/Treg cell responses (Figure S3D). These results highlight the potent immunomodulatory role of MCs that both augment (Shelburne et al., 2009) and regulate the quality (Mekori et al., 2016) of adaptive immunity. Together, these findings point to IL-9/MC-dependent negative activity on intestinal permeability that may account for inflammation, Candida dissemination, and dysregulated Th immunity.

**IL-9 Regulates IDO1 Activity**

TGF-β is known to provide long-term immune tolerance by regulating the activity of indoleamine 2,3-dioxygenase (IDO1) (Pallotta et al., 2011), known to be crucially involved in Treg-mediated memory responses to the fungus (De Luca et al., 2007; Montagnoli et al., 2002). Thus, the defective expansion of TGF-β-producing CTMCs in Il9R–/– mice would predict defective IDO1 activity in these mice. IDO1 expression was indeed defective in infection and particularly in re-infection in Il9R–/– mice as opposed to C57BL/6 mice (Figures 5A and 5B) and paralleled the decreased production of TGF-β observed in Il9R–/– and KitW/W-v mice (Figure 5C). The decreased expression of Ptpn6 (coding for SHP-1) (Figure 5D) causes a functional deficiency of TGF-β that is required for long-term tolerance (Pallotta et al., 2011). This finding suggests that IL-9 may regulate IDO1 activity via MC-dependent TGF-β production. This appeared to be the case because IL-9 activated Tgfb1, Ptpn6, and Ido1 genes (RT-PCR) (E) and production/phosphorylation of IDO1/STAT3 (F) in purified splenic dendritic cells pretreated for 1 hr with different doses of rIL-9 or sIL-9 before pulsing with the fungus for an additional 5 hr. (G) Tph1 expression (RT-PCR) in unstimulated MMCs and CTMCs and in the stomach of C57BL/6 and Il9R–/– mice. (H) Stomach histopathology (PAS; the scale bar represents 200 μm or 50 μm of C57BL/6 and Tph1–/– mice i.g. infected with C. albicans. (I) Fungal growth (log10 CFUs). (J) Foxp3 expression (RT-PCR) and IL-10 production (ELISA) in the stomach. Data represent pooled results (n = 6, mean ± SD) or representative images from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, knockdown versus C57BL/6 mice and rIL-9-treated versus untreated (0) cells. Unpaired t test or two-way ANOVA, Tukey’s or Bonferroni post test. R, 3 days after re-infection.
expanding inflammatory MMCs, eventually leading to barrier function loss; however, it was required for the activation of an optimal antifungal Th/Treg response by promoting IDO1 activity with the contribution of CTMCs producing TGF-β. However, MCs are also known to mediate immune suppression via Tph-1 (tryptophan hydroxylase-1), a synthase that catalyzes the conversion of tryptophan to serotonin (Nowak et al., 2012). When assessing the possible contribution of Tph-1, we found that CTMCs, but not MMCs, express Tph1 (Figure 5G) and that Tph1 expression was lower in Il9R−/− compared with C57BL/6 mice (Figure 5G). Consistent with the tolerogenic potential of Tph-1, inflammation (Figure 5H) and fungal growth (Figure 5I) were increased whereas tolerance decreased (Figure 5J) in Tph1−/− mice. Thus, CTMCs may contribute to ensure tolerance at the host/Candida interface through multiple mechanisms.

### IL-9 and MMCs Are Upregulated in Experimental Leaky Gut Models and CD Patients

To accommodate the above findings in a clinically relevant setting, we evaluated the presence of IL-9 and MC in experimental models of impaired barrier function, such as in homozygous F508del-Cftr C57BL/6 mice (CftrF508del/F508del, hereafter referred to as Cft(F508del) mice) or mice with gluten sensitivity (Papista et al., 2012) infected with C. albicans as well in duodenal biopsies from CD patients, scored according to the Marsh classification modified by Oberhuber et al. (1999) (AGA Institute, 2006). Cft(F508del) mice and mice with gluten sensitivity, although highly susceptible to C. albicans gastrointestinal infection in terms of fungal growth and inflammatory pathology (Figure S4), showed increased production of IL-9 (Figures 6A and 6E), increased Pu.1 and Ifi44 expression (Figures 6B and 6F), and increased MMC activity (Figures 6C and 6G). Consistent with the remarkable fungal dissemination to visceral organs (Figure S4), occludin expression was decreased in these mice (Figures 6D and 6H), a finding suggesting impaired intestinal permeability, to which the fungus greatly contributed. Promoted by these findings, we looked for IL-9 and MCs in CD patients in whom both Candida (Corouge et al., 2015; Nieuwenhuizen et al., 2003) and MCs (Frossi et al., 2017) contribute to pathology. IL-9 positivity was increased in duodenal biopsies from CD patients and correlated positively with infiltration of CD3+ T cells, CD117+, tryptase+ MCs, and disease severity and negatively with IDO1 expression (Figure 6f; Figure S5). Thus, IL-9/MMC expansion is a distinctive feature of disease severity in murine models of leaky gut, such as in the CF gut, gluten sensitivity, and human CD.

### DISCUSSION

This study shows a plausible mechanism by which C. albicans could promote either immune pathology or protective tolerance in the gut. It is well known that MCs and IL-9 are associated with intestinal diseases, from food allergy (Chen et al., 2015; Forbes et al., 2008) to inflammation (Bocckxstaens, 2015; Gerlach et al., 2014; Nalleweg et al., 2015; Weigmann and Neurath, 2017). However, that C. albicans was able to exploit the versatility of the IL-9/MC axis for balancing commensalism versus pathogenesis is an interesting finding. Consistent with the ability of MCs to respond to pathogens via Toll-like receptors (Abraham and St John, 2010), phagocytosis of the fungus by MCs was dependent on fungal morphotype and MC subtype, with hyphae promoting anti-inflammatory cytokine production by CTMCs and yeasts promoting MMC death and damage. IL-9 pivotally contributed to the discriminative responses of MCs. Produced by both MC types, in addition to ILC2s and Th9 cells, IL-9 stimulated secretion of proteases and cytokines, including its own. A positive amplification loop between ILC2s producing IL-9 and MMCs likely maximizes IL-9 production and promotes epithelial damage and inflammation. Thus, although exerting divergent antifungal effector activity, the different MCs, finely tuned by IL-9, appear to discriminate between fungal morphotypes and, in so doing, promote basal immune tolerance or epithelial damage.

Although the small intestine is usually considered the primary site of uptake of food antigens (Walker et al., 1972), uptake of food antigens can also occur in the stomach (Hatz et al., 1990). Therefore, C. albicans colonization of the stomach, where mastocytosis occurs, could be associated with barrier function loss, a finding suggesting a possible pathogenic role of the fungus in the development of gut diseases. In addition to known risk factors favoring fungal colonization in the stomach (Scott and Jenkins, 1982), epithelial damage promoted through MMC activation could be the key event promoting transition from fungal commensalism to pathogenesis, as already suggested (Moyes et al., 2016). Given the inflammatory activity of C. albicans-specific Th9 cells in the skin (Schlapbach et al., 2014), a pathogenic role for Th9 cells is also plausible. However, we found that Th9 cells are dispensable for immune pathology and are not detected under conditions of failure to activate Treg cells, leading to the clinically unwanted consequences of fungal colonization. However, the occurrence of Candida pneumonia in patients receiving imatinib mesylate treatment suggests that MC-targeted therapy might predispose patients to opportunistic and life-threatening fungal infections (Speletas et al., 2008). This study provides a plausible explanation for MC-mediated protection. Consistent with their immunoregulatory role in adaptive immune responses (Morita et al., 2016), tissue remodeling, homeostasis, and peripheral tolerance (Galli et al., 2008; Lu et al., 2006), CTMCs greatly contribute to the activation of intestinal immune tolerance via Tph1 and IDO1. That MCs transactivate IDO1 in dendritic cells (DCs) has already been described (Rodrigues et al., 2016). Here we found that IL-9 may not only directly affect IDO1 gene expression via STAT3...
Figure 6. IL-9/MMCs Are Expanded in Murine Models of Leaky Gut and in Human CD

(A–C) IL-9 production (A) (ELISA), Th9 cell-specific transcripts (B), and MC proteases (C) (RT-PCR) in the stomach of C57BL/6 and Cftr\(^{F508del}\) mice infected i.g. with C. albicans.

(D) Occludin expression by immunofluorescence in the gut of Cftr\(^{F508del}\) mice (the scale bar represents 100 \(\mu\)m).

(E–G) IL-9 production (E) (ELISA), expression of Th9-cell specific transcripts (F), and MC proteases (G) (RT-PCR) in the small intestine of gluten-sensitive BALB/c mice infected i.g. with C. albicans.

(H) Expression of occludin in the gut by immunofluorescence.

(I) IL-9 and IDO1 expression by immunofluorescence and detection of CD3\(^{+}\), CD117\(^{+}\), and tryptase\(^{+}\) cells by immunohistochemical staining in duodenal biopsies from patients with Marsh 1, Marsh 2, and Marsh 3 scores and controls (Ctrl). The scale bars represent 200 \(\mu\)m or 100 \(\mu\)m.

Data represent pooled results (n = 6, mean ± SD) or representative images from three experiments.

*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Cftr\(^{F508del}\) versus C57BL/6; gliadin and infected versus gliadin or infected mice. Unpaired t test or two-way ANOVA, Bonferroni post test.
and late, respectively, during which Clostridiaceae and Enterobacteriaceae expanded early. Interestingly, TGF-β production by MCs in response to IL-9 promotes lung fibrosis in aspergillosis (Moretti et al., 2017), a finding suggesting that modules of effector immunity may have different functional outcomes contingent upon the context.

Tryptophan abundance under conditions of defective host IDO1 expression is known to expand L. reuteri, which provides colonization resistance to Candida via the AhR/ILC3/IL-22 axis (Zelante et al., 2013). All of these microbial signatures were present in IDO1−/− mice and were responsible for the decreased inflammatory pathology and increased antifungal resistance. Indeed, Firmicutes were more abundant in IDO1−/− mice, with Lactobacillaceae represented more than Clostridiaceae in IDO1−/− mice and Clostridiaceae more than Lactobacillaceae in KitW/W-v mice, with Lactobacillaceae represented more than Clostridiaceae in IDO1−/− mice and Clostridiaceae more than Lactobacillaceae in KitW/W-v mice (Figure S6A). Of interest, L. johnsonii was abundant in both C57BL/6 and IDO1−/− mice, but L. reuteri was expanded in IDO1−/− mice either uninfected or in infection (Figure S6B). and, consistently, AhR expression, IL-22 production (Figure S6C), and Lcn2 expression (Figure S6D) were all increased in these mice. Microbiota transplantation between C57BL/6 and IDO1−/− mice revealed that antifungal resistance was increased and inflammation decreased in C57BL/6 mice receiving fecal content from IDO1−/− mice, whereas the opposite occurred in IDO1−/− mice transplanted with C57BL/6 feces (Figures S6E–S6G). This points to the contribution of local microbiota to antifungal resistance and mucosal homeostasis under conditions of IL-9 and, likely, MC deficiency, a finding also confirmed by the increased inflammatory pathology observed upon antibiotic treatment (Figures S6H and S6I).

Thus, the microbiota provides antifungal resistance under conditions of IL-9 deficiency much like in IDO1 deficiency. However, one most interesting and unexplained finding is the failure of the microbiota to provide antifungal resistance in re-infection, which suggests that dysregulated adaptive immunity affects the function of the microbiota. It is also likely that the activity of adaptive immunity encompasses an effect on MC plasticity (Daéron, 2016), including the ability of MCs to act as intestinal sensors of local microbiota. Indeed, we found a unique pattern of intestinal dysbiosis in MC-deficient mice in which Clostridiaceae and Enterobacteriaceae expanded early and late, respectively, during Candida colonization, suggesting a specific temporal pattern of MC-dependent regulation of local microbial composition. How nutrient availability, promotion of inflammation, or lack of tolerance contribute to microbial sensing and regulation by MCs at mucosal surfaces remains to be determined. Dysbiosis is a known risk factor for CD (Girbovan et al., 2017) and intestinal inflammation in CF (Garg and Ooi, 2017), conditions under which persistent symptoms are associated with a higher relative abundance of Proteobacteria and a lower abundance of Bacteroidetes and Firmicutes. This study provide evidence that the relatively high levels of IL-9 and MMCs observed in biopsies from patients with CD may promote inflammation-driven intestinal dysbiosis to which tryptophan deficiency may contribute. Thus, the IL-9/MC axis, by integrating signals derived from perturbed host/microbiota homeostasis, may act as a signature that discriminates between the pathogenic versus protective role of the fungus in the gut.

**EXPERIMENTAL PROCEDURES**

**Mice**

C57BL/6, Rag2−/− and BALB/c mice were purchased from Charles River Laboratories (Calco, Italy). Homozygous MC-deficient C57BL/6-KiW/v, Tph1−/−, Il4−/−, and Il17Rα−/− mice were bred under specific pathogen-free conditions in the animal facility at the University of Perugia. Il9R−/− and Rag2−/−Il9R−/− mice were kindly provided by Prof. Jean-Christophe Renaud (Ludwig Institute for Cancer Research, Brussels). Cf mice homozygous for the Phe508del-CFTR allele were described previously (Romans et al., 2017). Murine experiments were performed according to Italian Approved Animal Welfare Authorization 360/2015-PR and Legislative Decree 26/2014 regarding the animal license obtained by the Italian Ministry of Health lasting for 5 years (2015–2020). 5- to 8-week-old male and female mice were used in all experiments.

**Infection and In Vivo Treatment**

Candida albicans SC5314 cells were propagated on Sabouraud glucose agar at 37°C (Sigma-Aldrich, Milan, Italy). Gastrointestinal infection was performed by inoculating mice intra-gastrically (i.g.) with 10 × 10^6 Candida albicans cells in 200 μL saline using an 18G 4-cm-long plastic catheter. Re-infection was performed by i.g. inoculation of 10 × 10^6 Candida albicans cells 15 days after the primary infection. Mice were sacrificed 3 days after re-infection. Fungal growth was expressed as colony-forming units (cfu) per organ, obtained by serially diluting homogenates on Sabouraud agar plates incubated at 35°C for 24 hr. Murine monoclonal anti-IL-9 antibody (clone MM9C1, Bio X Cell) or control isotype IgG (clone C1.18.4, Bio X Cell) were administered intraperitoneally (i.p.) at a dose of 10 mg/kg for a week starting on the day of infection (from 34.33 ± 68.07 pg/mL to undetectable levels in the stomach, untreated versus treated mice at 3 dpi). Recombinant (r)IL-9 (R&D Systems) was administered i.p. at a dose of 10 μg/kg.

**Patients and Control Subjects**

Biopsy specimens were obtained from the distal duodenum during upper gastrointestinal endoscopy from 8 adult patients undergoing diagnostic protocols at the University Hospital of Perugia. No individual patient identification was involved, and no study-driven clinical intervention was performed; therefore, no ethical approval was necessary. The CD diagnosis was established according to standard criteria, including human leukocyte antigen (HLA) genotyping, anti-TG2 serum titer measurement, and histologic analysis. Intestinal biopsy specimens were evaluated for villous architecture, crypt height, and intraepithelial lymphocytes and scored according to the Marsh classification modified by Oberhuber et al. (1999). Control samples with normal intestinal histology were obtained from 3 subjects without CD undergoing biopsies for screening procedures for abdominal symptoms and excluded from CD diagnosis.

**Statistical Analysis**

GraphPad Prism software 6.01 (GraphPad) was used for analysis. Data are expressed as means ± SD. Horizontal bars indicate the means. Statistical significance was calculated by one- or two-tailed Student’s t test for single comparisons. Statistical analysis of the survival curves was performed using log rank (Mantel-Cox) test. The distribution of levels tested by Kolmogorov-Smirnov normality test turned out to be non-significant. Fluorescence intensity was measured using ImageJ software. Cell fluorescence intensity was measured using ImageJ software. The co-localization program Fiji with the Just Another Co-localization Plugin (JACoP) was used to quantify the degree of overlap by calculating the co-localization coefficients (Pearson’s correlation coefficient). The variance was similar in the groups being compared.
SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and six figures and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.04.034.

ACKNOWLEDGMENTS

This study was supported by the European Research Council (Specific Targeted Research Project FunMeta, ERC-2011-AdG-293714 to L.R.).

AUTHOR CONTRIBUTIONS

G.R. and V.O. designed the experiments and performed most of the in vitro and in vivo experiments. M. Borghi performed immunofluorescence experiments. T.Z., G.P., and M.D.Z. performed experiments with mastocytes. V.R.V. performed experiments in gluten-sensitive mice. V.R., R.D.S., M. Baldoni, and A.S. followed patients and provided clinical samples. J.-C.R. provided the knockout mice. A.B., S.M., C.C., E.G., L.M., C.P., and L.R. designed the experiments, analyzed the data, and wrote the paper.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 28, 2017
Revised: February 14, 2018
Accepted: April 5, 2018
Published: May 8, 2018

REFERENCES

Abraham, S.N., and St John, A.L. (2010). Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440–452.

AGA Institute (2006). AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 131, 1977–1980.

Becker, K.L., Rösler, B., Wang, X., Lachmandas, E., Karnsteeg, M., Jacobs, C.W., Joosten, L.A., Neeta, M.G., and van de Veendorck, F.L. (2016). Th2 and Th8 responses in patients with chronic mucocutaneous candidiasis and hyper-IgE syndrome. Clin. Exp. Allergy 46, 1564–1574.

Boecckstaens, G. (2015). Mast cells and inflammatory bowel disease. Curr. Opin. Pharmacol. 25, 45–49.

Bonifazi, P., Zelante, T., D’Angelo, C., De Luca, A., Moretti, S., Bozza, S., Perruccio, K., Iannitti, R.G., Giovannini, G., Volpi, C., et al. (2009). Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol. 2, 362–374.

Chen, C.Y., Lee, J.B., Liu, B., Ohta, S., Wang, P.Y., Kartashov, A.V., Mugge, L., Abonia, J.P., Barski, A., Izuhara, K., et al. (2015). Induction of Interleukin-9-Producing Mucosal Mast Cells Promotes Susceptibility to IgE-Mediated Experimental Food Allergy. Immunity 43, 788–802.

Corouge, M., Loridant, S., Fradin, C., Salleron, J., Damiens, S., Moragues, M.D., Souplet, V., Jouault, T., Robert, R., Dubucquoi, S., et al. (2015). Humoral immunity links Candida albicans infection and celiac disease. PLoS ONE 10, e0121776.

Da Rold, M. (2016). Innate myeloid cells under the control of adaptive immunity: the example of mast cells and basophils. Curr. Opin. Immunol. 38, 101–108.

De Luca, A., Montagnoli, C., Zelante, T., Bonifazi, P., Bozza, S., Moretti, S., D’Angelo, C., Vaccia, C., Boon, L., Bistoni, F., et al. (2007). Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of IRF. J. Immunol. 179, 5999–6008.

de Vries, H.C., and Noelle, R.J. (2010). Mast cell mediators in tolerance. Curr. Opin. Immunol. 22, 643–648.

Demoulin, J.B., Van Roost, E., Stevens, M., Groner, B., and Renault, J.C. (1999). Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J. Biol. Chem. 274, 25855–25861.

Elyaman, W., Bradshaw, E.M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Betteili, E., Oulka, M., van Snick, J., Renaud, J.C., et al. (2009). IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA 106, 12885–12890.

Forbes, E.E., Groschwitz, K., Abonia, J.P., Brandt, E.B., Cohen, E., Blanchard, C., Ahrens, R., Seidu, L., McKenzie, A., Strait, R., et al. (2008). IL-9 and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J. Exp. Med. 205, 897–913.

Frossi, B., Mion, F., Tripodo, C., Colombo, M.P., and Pulcini, C.E. (2017). Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. Trends Immunol. 38, 648–656.

Galli, S.J., Kalesnikoff, J., Grimbaldeston, M.A., Piliponsky, A.M., Williams, C.M., and Tsai, M. (2005). Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749–786.

Galli, S.J., Grimbaldeston, M., and Tsai, M. (2008). Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8, 478–486.

Garg, M., and Ooi, C.Y. (2017). The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy. Curr. Gastroenterol. Rep. 19, 6.

Gerard, R., Sendid, B., Colombel, J.F., Poulin, D., and Jouault, T. (2015). An immunological link between Candida albicans colonization and Crohn’s disease. Ctr. Rev. Microbiol. 41, 135–139.

Gerlach, K., Hwang, Y., Nikolaev, A., Atreya, R., Dornhoff, H., Steiner, S., Lehr, H.A., Wirtz, S., Vieth, M., Waisman, A., et al. (2014). TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 15, 676–686.

Gerlach, K., McKenzie, A.N., Neurath, M.F., and Weigmann, B. (2015). IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers 3, e983777.

Girbovan, A., Sur, G., Samasca, G., and Lupan, I. (2017). Dysbiosis a risk factor for celiac disease. Med. Microbiol. Immunol. (Berl.) 206, 83–91.

Godfraind, C., Louahed, J., Faulkner, H., Vink, A., Warinner, G., Gencris, R., and Renaud, J.C. (1998). Intraperitoneal inflammation by mast cells with both connective-tissue type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J. Immunol. 160, 3989–3996.

Goswami, R., Jabeen, R., Yagi, R., Pham, D., Zhu, J., Goenka, S., and Kaplan, M.H. (2012). STAT6-dependent regulation of Th9 development. J. Immunol. 188, 968–975.

Gurish, M.F., and Austen, K.F. (2012). Developmental origin and functional specialization of mast cell subsets. Immunity 37, 25–33.

Hatz, R.A., Bloch, K.J., Harmatz, P.R., Gonnella, P.A., Ariniello, P.D., Walker, W.A., and Kleinman, R.E. (1990). Divalent hapten-induced intestinal anaphylaxis in the mouse enhances macromolecular uptake from the stomach. Gastroenterology 98, 894–900.

Kaplan, M.H. (2013). Th9 cells: differentiation and disease. Immunol. Rev. 252, 104–115.

Lopes, J.P., Stylianou, M., Nilsson, G., and Urban, C.F. (2015). Opportunistic pathogen Candida albicans elicits a temporal response in primary human mast cells. Sci. Rep. 5, 12287.

Lu, L.F., Lind, E.F., Gonde, D.C., Bennett, K.A., Gleaner, M.W., Pino-Lagos, K., Scott, Z.A., Coyle, A.J., Reed, J.L., Van Snick, J., et al. (2006). Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442, 997–1002.

Malaviya, R., Ikeda, T., Ross, E., and Abraham, S.N. (1996). Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381, 77–80.

McDermott, J.R., Bartram, R.E., Knight, P.A., Miller, H.R., Garrod, D.R., and Gencris, R.K. (2003). Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc. Natl. Acad. Sci. USA 100, 7761–7766.
Mekori, Y.A., Hershko, A.Y., Fossii, B., Mion, F., and Pucillo, C.E. (2007). Mast cells in the promotion and limitation of chronic inflammation. J. Immunol. 169, 6238–6238.

Montagnoli, C., Bacci, A., Bozza, S., Gaziano, R., Mosci, P., Sharpe, A.H., and Romani, L. (2002). B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J. Immunol. 169, 6238–6238.

Moretti, S., Renga, G., Okonomou, V., Galosi, C., Pariano, M., Iannitti, R.G., Borghi, M., Puccetti, M., De Zuani, M., Pucillo, C.E., et al. (2017). A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat. Commun. 8, 14017.

Monta, H., Saito, H., Matsumoto, K., and Nakae, S. (2016). Regulatory roles of mast cells in immune responses. Semin. Immunopathol. 38, 623–629.

Moes, D.L., Wilson, D., Richardson, J.P., Mogavero, S., Tang, S.X., Wernecke, J., Hoffs, S., Gratacap, R.L., Robbins, J., Runglall, M., et al. (2016). Cytidialysin is a fungal toxin toxic for murine colonic epithelial cells. Nature 532, 64–68.

Nalleweg, N., Chiriac, M.T., Podstawa, E., Lehmann, C., Rau, T.T., Atreya, R., Krauss, E., Hunderfein, G., Fichtner-Feigl, S., Hartmann, A., et al. (2015). IL-9 and its receptor are predominantly involved in the pathogenesis of UC Gut. 64, 743–755.

Nieeuwenhuizen, W., Pieters, R.H., Knippel, L.M., Jansen, M.C., and Koppelman, S.J. (2003). Is Candida albicans a trigger in the onset of coeliac disease? Lancet 361, 2152–2154.

Noble, S.M., Gianetti, B.A., and Witchell, J.N. (2017). Candida albicans cell-type switching and functional plasticity in the mammalian host. Nat. Rev. Microbiol. 15, 96–108.

Nover, M.C., and Huffnagle, G.B. (2004). Does the microbiota regulate immune responses outside the gut? Trends Microbiol. 12, 562–568.

Nowak, E.C., de Vries, V.C., Wasiuk, A., Ahonen, C., Bennett, K.A., Le Mercier, I., Ha, D.G., and Noelle, R.J. (2012). Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J. Exp. Med. 209, 2127–2135.

Oberhuber, G., Granditsch, G., and Vogelsang, H. (1999). The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 11, 1185–1194.

Pallotta, M.T., Orabona, C., Volpi, C., Vaccia, C., Belladonna, M.L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011). Indoleamine 2,3-dioxigenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870–878.

Papista, C., Gerakopoulos, V., Kourouli, A., Souniadi, M., Kontana, A., Berthelot, L., Moura, I.C., Monteiro, R.C., and Yiannou, M. (2012). Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics. Lab. Invest. 92, 625–635.

Pilette, C., Ouadhri, Y., Van Snick, J., Renaud, J.C., Staat, P., Vaerman, J.P., and Sibille, Y. (2002). IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytes through TGF-beta. J. Immunol. 168, 4103–4111.

Reber, L.L., Sibillan, R., Mukai, K., and Galli, S.J. (2015). Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol. 8, 444–463.

Renaud, J.C., Goethals, A., Houssiau, F., Van Roost, E., and Van Snick, J. (1990). Cloning and expression of a cDNA for the human homolog of mouse T cell and mast cell growth factor P40. Cytokine 2, 9–12.

Rodrigues, C.P., Ferreira, A.C., Pinho, M.P., de Moraes, C.J., Bergami-Santos, P.C., and Barbuto, J.A. (2016). Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1–Expressing Mast Cells. Front. Immunol. 7, 9.

Romani, L. (2011). Immunity to fungal infections. Nat. Rev. Immunol. 11, 275–288.

Romani, L., Okonomou, V., Moretti, S., Iannitti, R.G., D’Adamo, M.C., Villella, V.R., Pariano, M., Storna, L., Borghi, M., Belet, M.M., et al. (2017). Thymosin α1 represents a potent potent single-molecule-based therapy for cystic fibrosis. Nat. Med. 23, 590–600.

Sasaki, K. (2012). Candida-associated gastric ulcer relapsing in a different position with a different appearance. World J. Gastroenterol. 18, 4450–4453.

Sclabach, C., Gehad, A., Yang, C., Watanabe, R., Guenova, E., Teague, J.E., Campbell, L., Yawalkar, N., Kupper, T.S., and Clark, R.A. (2014). Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci. Transl. Med. 6, 219ra8.

Schmitt, E., Klein, M., and Bopp, T. (2014). TH9 cells, new players in adaptive immunity. Trends Immunol. 35, 61–68.

Schuurhuf, A., Bont, L., Siezen, C.L., Hodemaekers, H., van Houwelingen, H.C., Kinman, T.G., Hoebee, B., Kimpen, J.L., and Janssen, R. (2010). Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr. Pulmonol. 45, 608–613.

Scott, B.B., and Jenkins, D. (1982). Gastro-oesophageal candidiasis. Gut 23, 137–139.

Shelburne, C.P., Nakano, H., St John, A.L., Chan, C., McLachlan, J.B., Gunn, M.D., Staats, H.F., and Abraham, S.N. (2009). Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 6, 331–342.

Shik, D., Tomar, S., Lee, J.B., Chen, C.Y., Smith, A., and Wang, Y.H. (2017). IL-9-producing cells in the development of IgE-mediated food allergy. Semin. Immunopathol. 39, 69–77.

Speletas, M., Vyzantiadis, T.A., Kalala, F., Plastiras, D., Kokoviadou, K., Antoniadis, A., and Korantzis, I. (2008). Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med. Mycol. 46, 259–263.

Trevisan, E., Vita, F., Medic, N., Soranzo, M.R., Zabucchi, G., and Borelli, V. (2014). Mast cells kill Candida albicans in the extracellular environment but spare ingested fungi from death. Inflammation 37, 2174–2189.

Underhill, D.M., and Peerman, E. (2015). Immune Interactions with Pathogenic and Commensal Fungi: A Two-Way Street. Immunity 43, 845–858.

Walker, W.A., Isselbacher, K.J., and Bloch, K.J. (1972). Intestinal uptake of Candida albicans in inflammatory bowel diseases. Semin. Immunopathol. 15, 954–960.

Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013). Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunol. 39, 372–385.